Calcium homeostasis in myogenic differentiation factor 1 (MyoD)-transformed, virally-transduced, skin-derived equine myotubes

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Fernandez Fuente, Marta ^a   Terracciano, Cesare M ^b   Martin Duque, Pilar ^c   Brown, Susan C ^a   Vassaux, Georges ^d   Piercy, Richard J ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

^d Laboratoire TIRO   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DANTROLENE; INDO 1; MYOD1 PROTEIN; RYANODINE RECEPTOR 1; TETRACAINE; THAPSIGARGIN; CAFFEINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; MYOD PROTEIN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CELL LINE; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FIBROBLAST CULTURE; HORSE; HUMAN; HUMAN CELL; MALIGNANT HYPERTHERMIA; MUSCLE CELL; MYOTUBE; NONHUMAN; RHABDOMYOLYSIS; SKIN FIBROBLAST; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HOMEOSTASIS; METABOLISM; SKELETAL MUSCLE; SKIN;

ANIMALS; CAFFEINE; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DANTROLENE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HOMEOSTASIS; HORSES; HUMANS; MUSCLE FIBERS, SKELETAL; MYOD PROTEIN; SKIN; THAPSIGARGIN; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84940280325     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105971     Document Type: Article

References (69)

1. Anderson K, Meissner G (1995) T-tubule depolarization-induced SR Ca2+ release is controlled by dihydropyridine receptor- and Ca (2+)-dependent mechanisms in cell homogenates from rabbit skeletal muscle. J Gen Physiol 105: 363-383.
2. Margreth A, Damiani E, Tobaldin G (1993) Ratio of dihydropyridine to ryanodine receptors in mammalian and frog twitch muscles in relation to the mechanical hypothesis of excitation-contraction coupling. Biochem Biophys Res Commun 197: 1303-1311.
3. Ma J, Anderson K, Shirokov R, Levis R, Gonzalez A, et al. (1993) Effects of perchlorate on the molecules of excitation-contraction coupling of skeletal and cardiac muscle. J Gen Physiol 102: 423-448. (Pubitemid 23307824)
4. Cherednichenko G, Hurne AM, Fessenden JD, Lee EH, Allen PD, et al. (2004) Conformational activation of Ca2+ entry by depolarization of skeletal myotubes. Proc Natl Acad Sci U S A 101: 15793-15798. (Pubitemid 39473567)
5. Huang J, van Breemen C, Kuo KH, Hove-Madsen L, Tibbits GF (2006) Store-operated Ca2 + entry modulates sarcoplasmic reticulum Ca2+ loading in neonatal rabbit cardiac ventricular myocytes. Am J Physiol Cell Physiol 290: C1572-1582. (Pubitemid 43830797)
6. Zhao X, Yoshida M, Brotto L, Takeshima H, Weisleder N, et al. (2005) Enhanced resistance to fatigue and altered calcium handling properties of sarcalumenin knockout mice. Physiol Genomics 23: 72-78.
7. Bannister RA, Pessah IN, Beam KG (2009) The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry. J Gen Physiol 133: 79-91.
8. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD (1962) Anaesthetic deaths in a family. Br J Anaesth 34: 395-396.
9. Healy JM, Lehane M, Heffron JJ, Farrell M, Johnson K, et al. (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-q13.2. Biochem Soc Trans 18: 326. (Pubitemid 20135999)
10. Hull MJ, Webster WW, Gatz E (1971) The effects of pentobarbital on 2,4-dinitrophenol induced malignant hyperthermia during halothane general anesthesia in dogs. J Oral Surg 29: 640-648.
11. Roberts MC, Mickelson JR, Patterson EE, Nelson TE, Armstrong PJ, et al. (2001) Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 95: 716-725.
12. Jurkat-Rott K, McCarthy T, Lehmann-Horn F (2000) Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23: 4-17. (Pubitemid 30013859)
13. Aleman M, Riehl J, Aldridge BM, Lecouteur RA, Stott JL, et al. (2004) Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Muscle Nerve 30: 356-365. (Pubitemid 39109001)
14. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, et al. (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448-451. (Pubitemid 21917175)
15. Harrison GG (1972) Pale, soft exudative pork, porcine stress syndrome and malignant hyperpyrexia - an identity? J S Afr Vet Assoc 43: 57-63.
16. Mickelson JR, Louis CF (1996) Malignant hyperthermia: excitation-contraction coupling, Ca2 + release channel, and cell Ca2+ regulation defects. Physiol Rev 76: 537-592.
17. Lopez JR, Alamo L, Caputo C, Wikinski J, Ledezma D (1985) Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 8: 355-358. (Pubitemid 17197961)
18. Lopez JR, Alamo LA, Jones DE, Papp L, Allen PD, et al. (1986) [Ca2+]i in muscles of malignant hyperthermia susceptible pigs determined in vivo with Ca2+ selective microelectrodes. Muscle Nerve 9: 85-86.
19. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, et al. (2001) Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 10: 2879-2887. (Pubitemid 34030919)
20. Ducreux S, Zorzato F, Muller C, Sewry C, Muntoni F, et al. (2004) Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 279: 43838-43846. (Pubitemid 39390690)
21. Ghassemi F, Vukcevic M, Xu L, Zhou H, Meissner G, et al. (2009) A recessive ryanodine receptor 1 mutation in a CCD patient increases channel activity. Cell Calcium 45: 192-197.
22. Zhou H, Brockington M, Jungbluth H, Monk D, Stanier P, et al. (2006) Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am J Hum Genet 79: 859-868. (Pubitemid 44763400)
23. Zhou H, Yamaguchi N, Xu L, Wang Y, Sewry C, et al. (2006) Characterization of recessive RYR1 mutations in core myopathies. Hum Mol Genet 15: 2791-2803. (Pubitemid 44400406)
24. Zvaritch E, Kraeva N, Bombardier E, McCloy RA, Depreux F, et al. (2009) Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc Natl Acad Sci U S A 106: 21813-21818.
25. Lynch PJ, Tong J, Lehane M, Mallet A, Giblin L, et al. (1999) A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. Proc Natl Acad Sci U S A 96: 4164-4169. (Pubitemid 29169054)
26. Avila G, O'Brien JJ, Dirksen RT (2001) Excitation - contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc Natl Acad Sci U S A 98: 4215-4220. (Pubitemid 32249924)
27. Zhou H, Rokach O, Feng L, Munteanu I, Mamchaoui K, et al. (2013) RyR1 deficiency in congenital myopathies disrupts excitation-contraction coupling. Hum Mutat 34: 986-996.
28. Voermans NC, Laan AE, Oosterhof A, van Kuppevelt TH, Drost G, et al. (2012) Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: a review of literature and a cross-sectional clinical study in 17 patients. Neuromuscul Disord 22: 944-954.
29. Hovnanian A (2007) SERCA pumps and human diseases. Subcell Biochem 45: 337-363.
30. Drogemuller C, Drogemuller M, Leeb T, Mascarello F, Testoni S, et al. (2008) Identification of a missense mutation in the bovine ATP2A1 gene in congenital pseudomyotonia of Chianina cattle: an animal model of human Brody disease. Genomics 92: 474-477.
31. McCarthy TV, Quane KA, Lynch PJ (2000) Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15: 410-417. (Pubitemid 30331213)
32. Cole FL, Mellor DJ, Hodgson DR, Reid SW (2004) Prevalence and demographic characteristics of exertional rhabdomyolysis in horses in Australia. Vet Rec 155: 625-630. (Pubitemid 39561908)
33. Upjohn MM, Archer RM, Christley RM, McGowan CM (2005) Incidence and risk factors associated with exertional rhabdomyolysis syndrome in National Hunt racehorses in Great Britain. Vet Rec 156: 763-766. (Pubitemid 40894907)
34. MacLeay JM, Sorum SA, Valberg SJ, Marsh WE, Sorum MD (1999) Epidemiologic analysis of factors influencing exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 60: 1562-1566. (Pubitemid 129536083)
35. Dranchak PK, Valberg SJ, Onan GW, Gallant EM, Binns MM, et al. (2006) Exclusion of linkage of the RYR1, CACNA1S, and ATP2A1 genes to recurrent exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 67: 1395-1400. (Pubitemid 44275495)
36. Isgren CM, Upjohn MM, Fernandez-Fuente M, Massey C, Pollott G, et al. (2010) Epidemiology of exertional rhabdomyolysis susceptibility in standardbred horses reveals associated risk factors and underlying enhanced performance. PLoS One 5: e11594.
37. Court MH, Engelking LR, Dodman NH, Anwer MS, Seeler DC, et al. (1987) Pharmacokinetics of dantrolene sodium in horses. J Vet Pharmacol Ther 10: 218-226.
38. McKenzie EC, Valberg SJ, Godden SM, Finno CJ, Murphy MJ (2004) Effect of oral administration of dantrolene sodium on serum creatine kinase activity after exercise in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 65: 74-79. (Pubitemid 38072458)
39. Bannister RA (2013) Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression. Biomed Res Int 2013: 390493.
40. Klein A, Lillis S, Munteanu I, Scoto M, Zhou H, et al. (2012) Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat 33: 981-988.
41. Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, et al. (2013) Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 23: 540-548.
42. Larach MG (1989) Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 69: 511-515.
43. Jungbluth H, Sewry CA, Muntoni F (2011) Core myopathies. Semin Pediatr Neurol 18: 239-249.
44. Burton NM, Vierck J, Krabbenhoft L, Bryne K, Dodson MV (2000) Methods for animal satellite cell culture under a variety of conditions. Methods Cell Sci 22: 51-61.
45. Yasin R, Van Beers G, Nurse KC, Al-Ani S, Landon DN, et al. (1977) A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J Neurol Sci 32: 347-360. (Pubitemid 8109814)
46. Lattanzi L, Salvatori G, Coletta M, Sonnino C, Cusella De Angelis MG, et al. (1998) High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 101: 2119-2128. (Pubitemid 28244096)
47. Abe T, Takano K, Suzuki A, Shimada Y, Inagaki M, et al. (2004) Myocyte differentiation generates nuclear invaginations traversed by myofibrils associating with sarcomeric protein mRNAs. J Cell Sci 117: 6523-6534. (Pubitemid 40214574)
48. Fernandez-Fuente M, Ames EG, Wagner ML, Zhou H, Strom M, et al. (2008) Assessment of the transformation of equine skin-derived fibroblasts to multinucleated skeletal myotubes following lentiviral-induced expression of equine myogenic differentiation 1. Am J Vet Res 69: 1637-1645.
49. Fernandez-Fuente M, Martin-Duque P, Vassaux G, Brown SC, Muntoni F, et al. (2014) Adenovirus-mediated expression of Myogenic Differentiation Factor 1 (MyoD) in equine and human dermal fibroblasts enables their conversion to caffeine-sensitive myotubes. Neuromuscul Disord: 24(3): 250-8.
50. Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, et al. (1990) MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci U S A 87: 7988-7992.
51. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, et al. (1989) Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A 86: 5434-5438. (Pubitemid 19185563)
52. Walmsley GL, Arechavala-Gomeza V, Fernandez-Fuente M, Burke MM, Nagel N, et al. (2010) A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One 5: e8647.
53. Larsen J, Pettersson OJ, Jakobsen M, Thomsen R, Pedersen CB, et al. (2011) Myoblasts generated by lentiviral mediated MyoD transduction of myotonic dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic molecules. BMC Res Notes 4: 490.
54. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514. (Pubitemid 28145972)
55. Rogers TB, Inesi G, Wade R, Lederer WJ (1995) Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Biosci Rep 15: 341-349. (Pubitemid 26050853)
56. Gyorke S, Lukyanenko V, Gyorke I (1997) Dual effects of tetracaine on spontaneous calcium release in rat ventricular myocytes. J Physiol 500 (Pt 2): 297-309. (Pubitemid 27193067)
57. Laver DR, van Helden DF (2011) Three independent mechanisms contribute to tetracaine inhibition of cardiac calcium release channels. J Mol Cell Cardiol 51: 357-369.
58. Yang T, Esteve E, Pessah IN, Molinski TF, Allen PD, et al. (2007) Elevated resting [Ca(2+)](i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am J Physiol Cell Physiol 292: C1591-1598. (Pubitemid 47080573)
59. Tong J, McCarthy TV, MacLennan DH (1999) Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. J Biol Chem 274: 693-702.
60. Csernoch L, Szentesi P, Sarkozi S, Szegedi C, Jona I, et al. (1999) Effects of tetracaine on sarcoplasmic calcium release in mammalian skeletal muscle fibres. J Physiol 515 (Pt 3): 843-857. (Pubitemid 29140117)
61. Garcia J, Avila-Sakar AJ, Stefani E (1991) Differential effects of ryanodine and tetracaine on charge movement and calcium transients in frog skeletal muscle. J Physiol 440: 403-417.
62. Hollingworth S, Chandler WK, Baylor SM (2006) Effects of tetracaine on voltage-activated calcium sparks in frog intact skeletal muscle fibers. J Gen Physiol 127: 291-307.
63. Eltit JM, Li H, Ward CW, Molinski T, Pessah IN, et al. (2011) Orthograde dihydropyridine receptor signal regulates ryanodine receptor passive leak. Proc Natl Acad Sci U S A 108: 7046-7051.
64. Eltit JM, Yang T, Li H, Molinski TF, Pessah IN, et al. (2010) RyR1-mediated Ca2+ leak and Ca2 + entry determine resting intracellular Ca2+ in skeletal myotubes. J Biol Chem 285: 13781-13787.
65. DiMaio Knych HK, Arthur RM, Taylor A, Moeller BC, Stanley SD (2011) Pharmacokinetics and metabolism of dantrolene in horses. J Vet Pharmacol Ther 34: 238-246.
66. McKenzie EC, Garrett RL, Payton ME, Riehl JH, Firshman AM, et al. (2010) Effect of feed restriction on plasma dantrolene concentrations in horses. Equine Vet J Suppl: 613-617.
67. Gissel H (2005) The role of Ca2+ in muscle cell damage. Ann N Y Acad Sci 1066: 166-180.
68. Glahn KP, Ellis FR, Halsall PJ, Muller CR, Snoeck MM, et al. (2010) Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 105: 417-420.
69. Lentz LR, Valberg SJ, Mickelson JR, Gallant EM (1999) In vitro contractile responses and contracture testing of skeletal muscle from Quarter Horses with exertional rhabdomyolysis. Am J Vet Res 60: 684-688. (Pubitemid 129543842)